24/7 Market News Snapshot 13 May, 2025 – Vaxart, Inc Common Stock (NASDAQ:VXRT)

May 13, 2025

DENVER, Colo., 13 May, 2025 (www.247marketnews.com) – (NASDAQ:VXRT) are discussed in this article.
Vaxart, Inc. (NASDAQ:VXRT) has demonstrated a resilient trading performance, opening at $0.41 and currently showing a 6.67% increase, reflecting strong investor interest with a trading volume of 5.25 million shares. Technical indicators suggest potential upward momentum, especially if the stock can maintain its current trajectory and break through nearby resistance levels. This positive market sentiment aligns well with recent developments in Vaxart’s vaccine development pipeline.

The company has recently lifted restrictions on its Phase 2b COVID-19 trial and is actively screening participants for a pivotal study involving 10,000 subjects, with dosing expected to start in the second quarter of 2025. Additionally, Vaxart has completed enrollment for its Phase 1 trial of a second-generation oral norovirus vaccine, with topline data anticipated by mid-2025. This trial evaluates both safety and immune response, paving the way for future studies, contingent upon partnerships or funding.

Vaxart has also made notable advancements with a new avian influenza vaccine candidate that has shown 100% protection in a ferret challenge model. This reinforces the company’s commitment to innovative vaccine solutions. In conjunction with these developments, Vaxart welcomed Jeroen Grasman as the new Chief Financial Officer, whose extensive background is expected to be beneficial as the company navigates its growth strategies.

The first quarter of 2025 has yielded a revenue increase to $20.9 million, driven by significant government contracts. With a cash runway projected to extend into 2026, Vaxart is strategically positioned to achieve upcoming regulatory milestones while maintaining cost efficiency. As the company continues its focus on developing effective vaccines, it aims to keep stakeholders informed of its progress and commitment to enhancing public health through advanced immunization technologies.

Related news for (VXRT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.